使用第二代基于人工智能的治疗方案进行的可行性开放式临床试验,用于用酶替代疗法治疗的Gaucher病患者
Noa Hurvitz1, Tama Dinur2, Shoshana Revel-Vilk2,3
1Departments of Medicine and Neurology, Hadassah Medical Center, Jerusalem 9112001, Israel.
Journal of clinical medicine
|June 19, 2024
概括
一种使用可变剂量进行酶替代疗法 (ERT) 的新型人工智能 (AI) 系统在高氏病1型 (GD1) 中显示可行性. 这种方法可以增强治疗反应,并克服ERT耐药性,患有这种罕见遗传疾病的患者.
科学领域:
- 生物化学和遗传学 生物化学和遗传学
- 医疗技术和人工智能
背景情况:
- 氏病1型 (GD1) 是一种遗传性疾病,由缺乏β-葡萄糖核糖酶酶引起,用酶替代疗法 (ERT) 治疗.
- 显著的一小部分GD1患者对标准ERT的反应不完全或减弱,表明需要优化治疗策略.
研究的目的:
- 评估第二代人工智能 (AI) 系统的可行性,以便在GD1患者中个性化,可变剂量的ERT.
- 探索人工智能驱动的剂量变化作为一种可能提高ERT疗效和解决治疗不响应问题的方法.
主要方法:
- 一个前性的,开放的,单中心的概念验证研究,涉及五名在ERT上的GD1患者.
- 利用Altus CareTM移动应用程序与人工智能算法生成个性化,随机的ERT剂量方案在医生定义的参数内.
- 变化包括剂量调整和改变服用时间.
主要成果:
- 由人工智能指导的可变剂量疗法在GD1患者中显示出稳定的ERT反应.
- 一名患者的生活质量得分 (SF-36) 和两名患者的健康感得到了改善.
- 两名患者的血小板数量增加,而血红蛋白水平保持稳定;注意到患者和护理人员的高度参与.
结论:
- 这项可行性研究表明,人工智能驱动的ERT剂量的变化有望提高高希氏病的治疗效率.
- 需要进一步进行广泛的临床试验来验证这些初步发现,并确定这种创新方法的长期益处.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.8K
10:15Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
Published on: March 22, 2017
7.0K
相关概念视频
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179